Hartaj Singh
Stock Analyst at Oppenheimer
(1.74)
# 3,384
Out of 5,152 analysts
106
Total ratings
46.32%
Success rate
-7.01%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $16.23 | +127.97% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $764.93 | +17.66% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $145.14 | -13.88% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $460.82 | - | 17 | Dec 19, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $53.78 | - | 6 | Dec 11, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $485.06 | +23.70% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $53.83 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $3.70 | +170.27% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.37 | +4,279.56% | 5 | May 30, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $2.51 | +258.57% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.68 | +2,280.95% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $11.62 | +89.33% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.90 | - | 4 | Jul 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $5.28 | +12,210.61% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $14.94 | +100.80% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $16.23
Upside: +127.97%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $764.93
Upside: +17.66%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $145.14
Upside: -13.88%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $460.82
Upside: -
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $53.78
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $485.06
Upside: +23.70%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $53.83
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $3.70
Upside: +170.27%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.37
Upside: +4,279.56%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $2.51
Upside: +258.57%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.68
Upside: +2,280.95%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $11.62
Upside: +89.33%
Jul 5, 2023
Downgrades: Perform
Price Target: n/a
Current: $0.90
Upside: -
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $5.28
Upside: +12,210.61%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $14.94
Upside: +100.80%